The Phase 3 IDHENTIFY study evaluating enasidenib plus best supportive care (BSC) versus conventional care regimens, which included BSC only, azacitidine plus BSC, low-dose cytarabine plus BSC, or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint of OS in patients with R/R AML with an IDH2 mutation. This evidence concerns the gene IDH2 and acute myeloid leukemia.